产品
编 号：F715422
分子式：C22H18ClF3N6O
分子量：474.87
分子式：C22H18ClF3N6O
分子量：474.87
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2402772-45-4
产品详情
生物活性：
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.
体内研究：
ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently.Animal Model:Male Konmin mice (8-week old, 22-25 g)
Dosage:20, 40 mg/kg
Administration:Orally; once daily for two weeks
Result:Prominently reduced CCl4-induced hepatic fibrosis level.
体外研究：
ATX inhibitor 5 (compound 10g) (IC50s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC).ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β.
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.
体内研究：
ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently.Animal Model:Male Konmin mice (8-week old, 22-25 g)
Dosage:20, 40 mg/kg
Administration:Orally; once daily for two weeks
Result:Prominently reduced CCl4-induced hepatic fibrosis level.
体外研究：
ATX inhibitor 5 (compound 10g) (IC50s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC).ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备